Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vernal conjunctivitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44294   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Vernal conjunctivitis. Displaying page 1 of 1.
    EudraCT Number: 2006-000319-96 Sponsor Protocol Number: NVG 05L101 Start Date*: 2006-06-05
    Sponsor Name:Novagali Pharma SA
    Full Title: “Estudio de fase II/III, Multicéntrico, doble enmascarado, Aleatorizado, de Grupos paralelos, Con variacion de dósis, controlado para valorar la eficacia y seguridad de NOVA22007 (emulsión ocular c...
    Medical condition: Queratoconjuntivitis vernal
    Disease: Version SOC Term Classification Code Term Level
    8.0 10047317 LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-001910-15 Sponsor Protocol Number: V034.04 Start Date*: 2004-11-22
    Sponsor Name:Stallergenes S.A.
    Full Title: Randomised, double-blind, placebo-controlled, multinational, multi-centre, Phase IIb / III study of the efficacy and safety of three doses of sublingual immunotherapy (SLIT) administered as tablets...
    Medical condition: Grass Pollen Related Allergic Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10010744 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) HU (Completed) DE (Completed) AT (Completed) IT (Completed) ES (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002835-40 Sponsor Protocol Number: AK701 Start Date*: 2020-01-28
    Sponsor Name:Akari Therapeutics Plc
    Full Title: Topical rVA576 for treatment of atopic keratoconjunctivitis: a randomised placebo double masked parallel trial (TRACKER)
    Medical condition: Moderate to severe atopic keratoconjunctivitis (AKC), Vernal keratoconjunctivitis (VKC), Severe allergic conjunctivitis (seasonal (SAC) or perennial (PAC))
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10069664 Atopic keratoconjunctivitis PT
    21.0 10015919 - Eye disorders 10081000 Vernal keratoconjunctivitis PT
    21.0 10015919 - Eye disorders 10081002 Vernal keratoconjunctivitis perennial LLT
    20.0 10015919 - Eye disorders 10001709 Allergic conjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002502-34 Sponsor Protocol Number: VO42.05 Start Date*: 2005-12-05
    Sponsor Name:Stallergenes S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III paediatric study of the efficacy and safety of one dose of sublingual immunotherapy (SLIT) administered as al...
    Medical condition: Grass Pollen Related Allergic Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10010744 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) DE (Completed) DK (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002501-23 Sponsor Protocol Number: V040.05 Start Date*: 2005-12-12
    Sponsor Name:Stallergenes S.A
    Full Title: A randomised, double-blind, placebo-controlled, multi-national, multi-centre, phase III extension study to assess the long term efficacy, safety and carry-over effect of one dose of sublingual imm...
    Medical condition: Grass Pollen Related Allergic Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10010744 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended) CZ (Completed) SK (Completed) ES (Completed) DK (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005060-10 Sponsor Protocol Number: NVG09B113 Start Date*: 2013-04-08
    Sponsor Name:Novagali Pharma S.A.S.
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-MASKED, 3 PARALLEL ARMS, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NOVA22007 1MG/ML (CICLOSPORIN/CYCLOSPORINE) EYE DROPS, EMULSION ADMINISTERED...
    Medical condition: Vernal Keratoconjunctivitis (VKC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10057383 Allergic keratoconjunctivitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed) DE (Completed) PT (Completed) ES (Completed) GR (Completed) HR (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003906-32 Sponsor Protocol Number: V060.08 Start Date*: 2008-11-26
    Sponsor Name:Stallergenes S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multi national, Phase III study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT), starting 2 months before the grass pollen seaso...
    Medical condition: Grass pollen allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039085 Rhinitis allergic LLT
    9.1 10039085 Rhinitis allergic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004825-40 Sponsor Protocol Number: AB0801 Start Date*: 2008-12-01
    Sponsor Name:Artu Biologicals Europe BV
    Full Title: A randomised, double-blind, placebo-controlled, long-term Phase III study to assess the efficacy and safety of Oralgen® Grass Pollen in patients with grass pollen-related allergic rhinoconjunctivitis.
    Medical condition: Allergic Rhinoconjunctivitis due to grass pollen allergy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) FR (Ongoing) BE (Completed) DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA